AU2022410335A1 - Treatment using heterodimeric relaxin fusions - Google Patents

Treatment using heterodimeric relaxin fusions Download PDF

Info

Publication number
AU2022410335A1
AU2022410335A1 AU2022410335A AU2022410335A AU2022410335A1 AU 2022410335 A1 AU2022410335 A1 AU 2022410335A1 AU 2022410335 A AU2022410335 A AU 2022410335A AU 2022410335 A AU2022410335 A AU 2022410335A AU 2022410335 A1 AU2022410335 A1 AU 2022410335A1
Authority
AU
Australia
Prior art keywords
relaxin
chain
amino acid
fusion
heterodimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022410335A
Other languages
English (en)
Inventor
Kathleen Marie CONNOLLY
Anders GABRIELSEN
Richard Thomas GEORGE JR
Sami Ali Abdel Hafees OMAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
MedImmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune Ltd filed Critical MedImmune Ltd
Publication of AU2022410335A1 publication Critical patent/AU2022410335A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2022410335A 2021-12-15 2022-12-14 Treatment using heterodimeric relaxin fusions Pending AU2022410335A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163289687P 2021-12-15 2021-12-15
US63/289,687 2021-12-15
US202263386812P 2022-12-09 2022-12-09
US63/386,812 2022-12-09
PCT/EP2022/086001 WO2023111112A1 (en) 2021-12-15 2022-12-14 Treatment using heterodimeric relaxin fusions

Publications (1)

Publication Number Publication Date
AU2022410335A1 true AU2022410335A1 (en) 2024-07-18

Family

ID=84888900

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022410335A Pending AU2022410335A1 (en) 2021-12-15 2022-12-14 Treatment using heterodimeric relaxin fusions

Country Status (8)

Country Link
US (1) US20250295737A1 (https=)
EP (1) EP4447998A1 (https=)
JP (1) JP2024546877A (https=)
KR (1) KR20240121820A (https=)
AU (1) AU2022410335A1 (https=)
CA (1) CA3241355A1 (https=)
IL (1) IL313386A (https=)
WO (1) WO2023111112A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118510536A (zh) 2021-11-11 2024-08-16 泰克托尼治疗股份有限公司 松弛素-2融合蛋白类似物及其使用方法
CN120813595A (zh) 2023-03-03 2025-10-17 阿斯利康(瑞典)有限公司 包含异源二聚体松弛素融合蛋白的药物制剂及其用途
AU2024270919A1 (en) 2023-05-18 2026-01-15 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
RU2014103288A (ru) 2011-07-01 2015-08-10 Байер Интеллектчуал Проперти Гмбх Слитые полипептиды релаксина и их применение
KR20140039257A (ko) * 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
EP3574004A1 (en) 2017-01-25 2019-12-04 Medimmune, LLC Relaxin fusion polypeptides and uses thereof
CN115768801A (zh) * 2020-05-08 2023-03-07 哈佛学院院长等 工程化松弛素及其使用方法

Also Published As

Publication number Publication date
IL313386A (en) 2024-08-01
US20250295737A1 (en) 2025-09-25
JP2024546877A (ja) 2024-12-26
CA3241355A1 (en) 2023-06-22
KR20240121820A (ko) 2024-08-09
EP4447998A1 (en) 2024-10-23
WO2023111112A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
AU2024200074B2 (en) Heterodimeric relaxin fusions and uses thereof
US11845782B2 (en) Relaxin fusion polypeptides and uses thereof
US20250295737A1 (en) Treatment Using Heterodimeric Relaxin Fusions
US12264188B2 (en) Relaxin-2 fusion proteins
TW202426037A (zh) 使用異二聚鬆弛素融合物之治療方法
WO2024121362A1 (en) Dosing regimens using heterodimeric relaxin fusions
EA052557B1 (ru) Лечение с применением гетеродимерных слитых продуктов на основе релаксина
CN118434437A (zh) 使用异源二聚体松弛素融合物进行的治疗
EA049488B1 (ru) Гетеродимерные слитые продукты на основе релаксина и пути их применения